Related Experiment Video
Updated: Dec 25, 2025
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
SIRT3 increases cisplatin sensitivity of small-cell lung cancer through apoptosis
Rui Guo1, Yang Li2, Yanan Xue2
1Department of Pathophysiology, College of Basic Medical Science, Jilin University, Changchun 130021, PR China; College of Basic Medical Science, Hebei North College, Zhangjiakou, Hebei 075000, PR China.
Abstract:
Small-cell lung cancer (SCLC) is the most invasive of all lung cancer subtypes, and is characterized by its rapid response to chemotherapy resistance. Overcoming chemotherapy resistance is therefore the key to treating SCLC. P53 is mutated in most SCLCs, which has an effect of enhancing chemotherapy resistance. Regulation of p53 proteins by a variety of post-translational modifications, such as acetylation, which affects their function. Acetylation and deacetylation of p53 may be potential targets for modulating chemosensitivity. Recent studies have shown that SIRT3 acts as a deacetylase that regulates acetylation of p53. However, whether SIRT3 can regulate the post-translational modification of mutant p53 has not been studied. In the present study, we found that SIRT3 can deacetylate mutant p53, thus reducing its expression, inducing apoptosis in SCLC cells, and increasing SCLC chemosensitivity. The relationship between SIRT3 and mutant p53 could be the basis of a new SCLC treatment approach.
Insights
This study reveals that SIRT3 deacetylates mutant p53, reducing its expression and inducing apoptosis in small-cell lung cancer (SCLC) cells. This finding offers a potential new strategy for overcoming chemotherapy resistance in SCLC treatment.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Small-cell lung cancer (SCLC) exhibits rapid chemotherapy resistance, necessitating novel treatment strategies.
- Mutated p53 is common in SCLC and contributes to chemotherapy resistance.
- Post-translational modifications, like acetylation, regulate p53 function and chemosensitivity.
Purpose of the Study:
- To investigate whether SIRT3, a deacetylase, can regulate the post-translational modification of mutant p53 in SCLC.
- To determine the effect of SIRT3 on mutant p53 expression, apoptosis, and chemosensitivity in SCLC cells.
Main Methods:
- Investigated the interaction between SIRT3 and mutant p53.
- Assessed the impact of SIRT3 on mutant p53 deacetylation and expression levels.
- Evaluated the effects on SCLC cell apoptosis and chemosensitivity.
Main Results:
- SIRT3 was found to deacetylate mutant p53.
- Deacetylation of mutant p53 by SIRT3 led to reduced mutant p53 expression.
- This process induced apoptosis in SCLC cells and enhanced chemosensitivity.
Conclusions:
- SIRT3 plays a role in regulating mutant p53 through deacetylation.
- Targeting the SIRT3-mutant p53 interaction may represent a novel therapeutic approach for SCLC.
- This pathway could be key to overcoming chemotherapy resistance in SCLC.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
09:40Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024